Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Executives withdraw acquisition offer for Tongjitang

This article was originally published in Scrip

Executive Summary

Tongjitang Chinese Medicines said that an offer made by two executives to acquire the company has been withdrawn. The firm's chairman and CEO, Xiaochun Wang, and Yongcun Chen, a director, withdrew their $2.55 per share offer because of the recent deterioration of the credit market. The withdrawal means that the firm, which went public in March 2007, will remain listed in the New York stock exchange. Tongjitang, which is based in Shenzhen, China, develops and markets pharmaceuticals based on traditional Chinese medicines in China.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts